Prevalence and risk factors related to haloperidol use for delirium in adult intensive care patients: the multinational AID-ICU inception cohort study.

Collet, Marie O; Caballero, Jesús; Sonneville, Romain; Bozza, Fernando A; Nydahl, Peter; Schandl, Anna; Wøien, Hilden; Citerio, Giuseppe; van den Boogaard, Mark; Hästbacka, Johanna; Hänggi, Matthias; Colpaert, Kirsten; Rose, Louise; Barbateskovic, Marija; Lange, Theis; Jensen, Aksel; Krog, Martin B; Egerod, Ingrid; Nibro, Helle L; Wetterslev, Jørn; ... (2018). Prevalence and risk factors related to haloperidol use for delirium in adult intensive care patients: the multinational AID-ICU inception cohort study. Intensive care medicine, 44(7), pp. 1081-1089. Springer 10.1007/s00134-018-5204-y

[img] Text
2018 - Collet - ICM - PMID 29767323.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (961kB) | Request a copy

PURPOSE We assessed the prevalence and variables associated with haloperidol use for delirium in ICU patients and explored any associations of haloperidol use with 90-day mortality. METHODS All acutely admitted, adult ICU patients were screened during a 2-week inception period. We followed the patient throughout their ICU stay and assessed 90-day mortality. We assessed patients and their variables in the first 24 and 72 h in ICU and studied their association together with that of ICU characteristics with haloperidol use. RESULTS We included 1260 patients from 99 ICUs in 13 countries. Delirium occurred in 314/1260 patients [25% (95% confidence interval 23-27)] of whom 145 received haloperidol [46% (41-52)]. Other interventions for delirium were benzodiazepines in 36% (31-42), dexmedetomidine in 21% (17-26), quetiapine in 19% (14-23) and olanzapine in 9% (6-12) of the patients with delirium. In the first 24 h in the ICU, all subtypes of delirium [hyperactive, adjusted odds ratio (aOR) 29.7 (12.9-74.5); mixed 10.0 (5.0-20.2); hypoactive 3.0 (1.2-6.7)] and circulatory support 2.7 (1.7-4.3) were associated with haloperidol use. At 72 h after ICU admission, circulatory support remained associated with subsequent use of haloperidol, aOR 2.6 (1.1-6.9). Haloperidol use within 0-24 h and within 0-72 h of ICU admission was not associated with 90-day mortality [aOR 1.2 (0.5-2.5); p = 0.66] and [aOR 1.9 (1.0-3.9); p = 0.07], respectively. CONCLUSIONS In our study, haloperidol was the main pharmacological agent used for delirium in adult patients regardless of delirium subtype. Benzodiazepines, other anti-psychotics and dexmedetomidine were other frequently used agents. Haloperidol use was not statistically significantly associated with increased 90-day mortality.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Intensive Care, Emergency Medicine and Anaesthesiology (DINA) > Clinic of Intensive Care

UniBE Contributor:

Hänggi, Matthias

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0342-4642

Publisher:

Springer

Language:

English

Submitter:

Mirella Aeberhard

Date Deposited:

04 Jun 2018 16:02

Last Modified:

04 Nov 2019 08:09

Publisher DOI:

10.1007/s00134-018-5204-y

PubMed ID:

29767323

Uncontrolled Keywords:

Cohort Critical care Delirium Haloperidol ICU

BORIS DOI:

10.7892/boris.116975

URI:

https://boris.unibe.ch/id/eprint/116975

Actions (login required)

Edit item Edit item
Provide Feedback